HZA-018 is under clinical development by Hangzhou Hezheng Pharmaceutical and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to GlobalData, Phase I drugs for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HZA-018’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HZA-018 is under development for the treatment of B cell lymphomas including chronic lymphocytic leukemia, small-cell lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia, diffuse large B-cell lymphoma and relapsed or refractory primary or secondary central nervous system lymphoma. The therapeutic candidate is formulated as capsule and administered by oral route. It targets Bruton’s tyrosine kinase (BTK).
For a complete picture of HZA-018’s drug-specific PTSR and LoA scores, buy the report here.